799-ICRAFT: for Dual-Action Cancer Targets
Researchers have developed ICRAFT, an interactive computational platform designed to identify gene targets that enhance cancer immunotherapy. Unlike previous tools that focus on a single cell type, this resource integrates CRISPR screens and transcriptomic data to discover pathways with dual action in both cancer and T cells. The platform identified TNFAIP3 as a primary target whose deletion significantly improves anti-tumor immunity. In cancer cells, removing this gene increases susceptibility to immune-mediated killing, while in T cells, it boosts cytotoxic activity. Ultimately, ICRAFT…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.